Pancreatic Cancer Research

ResearcherChongqing UniversityActive in the last 2 years

Jingyang Yin

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5012371913. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 5 papers · 2026: 2 papers

Papers 12

  1. An Exosomal Signature for Preoperative Detection of Occult Liver Metastasis in Pancreatic Cancer. First author DOI 10.1001/jamasurg.2026.3840↗
  2. A promising magnesium-related alloy with metabolic reprogramming and antitumor effects in hepatocellular and pancreatic cancer. Co-author DOI 10.1016/j.bioactmat.2025.12.039↗
  3. Disulfidptosis: a novel gene-based signature predicts prognosis and immunotherapy efficacy of pancreatic adenocarcinoma. Co-author DOI 10.1007/s12672-025-02053-w↗
  4. Establishment of M2 macrophage-related prognostic signature in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s12672-025-02838-z↗
  5. Increased PRIM2 Expression Associated With Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002387↗
  6. A novel protein cPFKFB4 encoded by hsa_circ_0065394 strengthens PKM2-mediated glucose metabolic reprogramming to facilitate pancreatic cancer progression under… Co-author DOI 10.1186/s12943-025-02500-w↗
  7. Circular RNA in Pancreatic Cancer: Biogenesis, Mechanism, Function and Clinical Application. Co-author DOI 10.7150/ijms.107773↗
  8. PRIM2 promotes proliferation and metastasis of pancreatic ductal adenocarcinoma through interactions with FAM111B. Co-author DOI 10.1007/s12032-024-02554-8↗
  9. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma. First author DOI 10.1186/s12935-022-02836-z↗
  10. The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway. Co-author DOI 10.3389/fonc.2023.1138238↗
  11. Corrigendum: The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway. Co-author DOI 10.3389/fonc.2023.1218781↗
  12. Increased expression of miR-194-5p through the circPVRL3/miR-194-5p/SOCS2 axis promotes proliferation and metastasis in pancreatic ductal adenocarcinoma by act… Co-author DOI 10.1186/s12935-022-02835-0↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huaizhi Wang · 9 shared papers, 2022–2025 · strength 2.18
  2. Shixiang Guo · 6 shared papers, 2022–2026 · strength 1.29
  3. Fuming Xie · 5 shared papers, 2022–2025 · strength 0.95
  4. Jian Li · 2 shared papers, 2023–2025 · strength 0.66
  5. Hang Chen · 2 shared papers, 2025 · strength 0.50
  6. Hui Chen · 2 shared papers, 2024–2025 · strength 0.49
  7. Bojing Chi · 3 shared papers, 2022–2023 · strength 0.45
  8. Wen Fu · 3 shared papers, 2022–2023 · strength 0.45
  9. Jianyou Gu · 2 shared papers, 2022–2026 · strength 0.40
  10. Lei Cai · 2 shared papers, 2022–2025 · strength 0.37
  11. Jianyou Gu · 2 shared papers, 2023 · strength 0.31
  12. Pijiang Sun · 1 shared paper, 2025 · strength 0.27
  13. Mitsuro Kanda · 1 shared paper, 2026 · strength 0.26
  14. Caiming Xu · 1 shared paper, 2026 · strength 0.26
  15. Mitsuo Shimada · 1 shared paper, 2026 · strength 0.26
  16. Takayuki Noma · 1 shared paper, 2026 · strength 0.26
  17. J.S. Zhang · 1 shared paper, 2026 · strength 0.26
  18. Vincent M. Chung · 1 shared paper, 2026 · strength 0.26
  19. Ajay Goel · 1 shared paper, 2026 · strength 0.26
  20. Song Cheol Kim · 1 shared paper, 2026 · strength 0.26
  21. Daniel D. Von Hoff · 1 shared paper, 2026 · strength 0.26
  22. Huaizhi Wang · 1 shared paper, 2025 · strength 0.25
  23. Xianxing Wang · 1 shared paper, 2024 · strength 0.24
  24. Bing Ni · 1 shared paper, 2023 · strength 0.24
  25. Wenhua Li · 1 shared paper, 2023 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.